Estimates Revisions Recursion Pharmaceuticals, Inc. Mexican S.E.
Stocks
RXRX *
US75629V1044
Biotechnology & Medical Research
|
End-of-day quote
Mexican S.E.
2026-10-06
|
5-day change | 1st Jan Change | ||
| 82.80 MXN | -4.83% |
|
+21.91% | +12.06% |
| 09-21 | Recursion Pharmaceuticals, Inc. Grants Tempus Ai, Inc. Non-Exclusive License for Rna Foundation Model | CI |
| 09-21 | Tempus AI, Recursion Extend Data License, Amend Fee Structure | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Recursion Pharmaceuticals, Inc.(RXRX)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Recursion Pharmaceuticals, Inc.(RXRX)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Recursion Pharmaceuticals, Inc.(RXRX)
EBIT
Dividend / Share (DPS)
Data source:
Recursion Pharmaceuticals, Inc.(RXRX)
Cash or Net Debt
- Stock Market
- Stocks
- RXRX Stock
- RXRX * Stock
- Consensus Recursion Pharmaceuticals, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
